Cigna drops coverage of GLP-1 obesity drugs for its own employees
Details of the change in the Cigna Group Medical Plan were announced in an email to employees on Monday.
A Cigna spokesperson confirmed that it was ending the coverage.
"As availability has increased and new options have emerged, we've made the decision to end our plan's coverage for GLP-1s for weight loss," the spokesperson said. "We remain committed to supporting our employees' health through a range of weight management programs and resources."
Wildly popular GLP-1 drugs like Wegovy and Zepbound promote weight loss by mimicking a hormone that keeps the stomach feeling full.
In a document circulated to employees, Cigna suggested those currently using the medications can choose to pay for the drugs with cash through manufacturer sites or TrumpRx.
The cash-pay purchases will not apply toward a deductible or the amount of spending required before enrollees can use their health coverage, the document said.
The price of weight-loss drugs has been dropping in 2026 with the launch of Novo's Wegovy pill and Lilly's oral Foundayo, which feature prices that start at
At the same time, employers have been cutting back on their coverage of the drugs.
The spokesperson said the change will not impact coverage for plans outside of Cigna's employee health plan or coverage of the drugs for the treatment of type 2 diabetes.
Those currently using the medications have until
Cigna said that for employees who had insurance approvals for the drugs, it would cover older, generic weight-loss drugs, including phentermine, diethylpropion, benzphetamine and phendimetrazine, which are less effective than GLP-1s.
The
The company had 67,700 employees at the end of 2025, 88% of whom were based in the



Invesco S&P 500 Equal Weight ETF $RSP Shares Bought by Erste Asset Management GmbH
Senior Market Sales® Fortifies Annuity Reach With Acquisition of Retirement Planning Firm Stratton & Company
Advisor News
- The 3 things that shrink your Social Security income
- Proposed legislation takes aim at Social Security shortfall
- The overlooked retirement security risk that must be addressed
- What advisors should know about hedge funds in retirement planning
- Retirement control is top success measure for middle class, ACLI says
More Advisor NewsAnnuity News
- Built-in guaranteed annuities: What advisors should know
- Malibu Life Holdings Completes Acquisition of TruSpire, Establishing Malibu USA and Accelerating Entry into the U.S. Retail Annuity Market
- Why job boards are failing insurance agencies
- MassMutual Ranks No. 100 on the 2026 Fortune 500® List
- What’s fueling record annuity growth?
More Annuity NewsHealth/Employee Benefits News
- Feds to decide fate of $2 billion California plan to fund Medi-Cal
- Obamacare premiums surged this year. A new analysis shows it's likely to happen again in 2027
- An aging population needs advisors to cut through the confusion
- Meet 'Project 2029' — and its war on the annoyance economy
- New Findings from Johns Hopkins University School of Medicine in the Area of Barth Syndrome Reported (AMCP Market Insights: Managed care considerations in Barth syndrome): Heart Disorders and Diseases – Barth Syndrome
More Health/Employee Benefits NewsLife Insurance News
- Best's Review Leaders Issue Ranks Top Global Brokers and More
- Fortitude Re Announces $3.8 Billion Long-Term Care Reinsurance Agreement with Unum Group
- Unum Group Announces $3.8 Billion Long-Term Care Reinsurance Transaction with Fortitude Re
- Before you debate premium financing, understand the bigger picture
- NAIFA praises House committee approval of Clarity for Compensation Act
More Life Insurance News